![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TPBG |
Gene summary for TPBG |
![]() |
Gene information | Species | Human | Gene symbol | TPBG | Gene ID | 7162 |
Gene name | trophoblast glycoprotein | |
Gene Alias | 5T4 | |
Cytomap | 6q14.1 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q13641 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7162 | TPBG | LP17 | Human | Oral cavity | LP | 4.08e-05 | 9.50e-01 | 0.2349 |
7162 | TPBG | SYSMH1 | Human | Oral cavity | OSCC | 1.44e-55 | 1.25e+00 | 0.1127 |
7162 | TPBG | SYSMH2 | Human | Oral cavity | OSCC | 6.51e-23 | 8.06e-01 | 0.2326 |
7162 | TPBG | SYSMH3 | Human | Oral cavity | OSCC | 8.97e-53 | 1.40e+00 | 0.2442 |
7162 | TPBG | SYSMH4 | Human | Oral cavity | OSCC | 2.42e-05 | 1.61e-01 | 0.1226 |
7162 | TPBG | SYSMH5 | Human | Oral cavity | OSCC | 1.94e-16 | 5.66e-01 | 0.0647 |
7162 | TPBG | SYSMH6 | Human | Oral cavity | OSCC | 1.96e-09 | 4.43e-01 | 0.1275 |
7162 | TPBG | GSM5252130_BPH340PrGF_Via | Human | Prostate | BPH | 1.41e-05 | 4.18e-01 | -0.1972 |
7162 | TPBG | GSM5252132_BPH389PrGF | Human | Prostate | BPH | 2.92e-04 | 6.68e-01 | -0.2247 |
7162 | TPBG | GSM5252134_BPH511PrG_Fcol_3GEX | Human | Prostate | BPH | 2.07e-07 | 4.35e-01 | -0.1433 |
7162 | TPBG | GSM5252135_BPH511PrPUr_Fcol_3GEX | Human | Prostate | BPH | 1.77e-09 | 5.78e-01 | -0.1833 |
7162 | TPBG | GSM5252136_BPH556PrGA1_Fcol | Human | Prostate | BPH | 1.19e-02 | 3.72e-01 | -0.23 |
7162 | TPBG | 047563_1562-all-cells | Human | Prostate | BPH | 6.61e-07 | -1.75e-01 | 0.0791 |
7162 | TPBG | Dong_P1 | Human | Prostate | Tumor | 5.72e-17 | 6.53e-02 | 0.035 |
7162 | TPBG | Dong_P3 | Human | Prostate | Tumor | 1.36e-10 | -3.25e-02 | 0.0278 |
7162 | TPBG | Dong_P4 | Human | Prostate | Tumor | 6.04e-03 | 8.28e-02 | 0.0292 |
7162 | TPBG | Dong_P5 | Human | Prostate | Tumor | 1.60e-26 | -3.67e-02 | 0.053 |
7162 | TPBG | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 1.37e-02 | -9.61e-02 | 0.1545 |
7162 | TPBG | P1_cSCC | Human | Skin | cSCC | 8.12e-24 | 9.57e-01 | 0.0292 |
7162 | TPBG | P2_cSCC | Human | Skin | cSCC | 1.54e-07 | 4.57e-01 | -0.024 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00016679 | Cervix | CC | ameboidal-type cell migration | 110/2311 | 475/18723 | 2.66e-11 | 6.36e-09 | 110 |
GO:007265910 | Cervix | CC | protein localization to plasma membrane | 73/2311 | 284/18723 | 4.95e-10 | 6.73e-08 | 73 |
GO:00160557 | Cervix | CC | Wnt signaling pathway | 98/2311 | 444/18723 | 4.82e-09 | 4.65e-07 | 98 |
GO:00321035 | Cervix | CC | positive regulation of response to external stimulus | 95/2311 | 427/18723 | 5.44e-09 | 5.03e-07 | 95 |
GO:01987387 | Cervix | CC | cell-cell signaling by wnt | 98/2311 | 446/18723 | 6.16e-09 | 5.58e-07 | 98 |
GO:19907788 | Cervix | CC | protein localization to cell periphery | 78/2311 | 333/18723 | 1.22e-08 | 9.73e-07 | 78 |
GO:00603267 | Cervix | CC | cell chemotaxis | 73/2311 | 310/18723 | 2.82e-08 | 1.96e-06 | 73 |
GO:00301117 | Cervix | CC | regulation of Wnt signaling pathway | 76/2311 | 328/18723 | 3.05e-08 | 2.08e-06 | 76 |
GO:00343298 | Cervix | CC | cell junction assembly | 88/2311 | 420/18723 | 3.42e-07 | 1.38e-05 | 88 |
GO:00163587 | Cervix | CC | dendrite development | 58/2311 | 243/18723 | 4.52e-07 | 1.76e-05 | 58 |
GO:00608287 | Cervix | CC | regulation of canonical Wnt signaling pathway | 58/2311 | 253/18723 | 1.83e-06 | 5.89e-05 | 58 |
GO:00600707 | Cervix | CC | canonical Wnt signaling pathway | 66/2311 | 303/18723 | 2.47e-06 | 7.35e-05 | 66 |
GO:00509203 | Cervix | CC | regulation of chemotaxis | 51/2311 | 223/18723 | 8.03e-06 | 1.86e-04 | 51 |
GO:00434104 | Cervix | CC | positive regulation of MAPK cascade | 90/2311 | 480/18723 | 2.92e-05 | 4.83e-04 | 90 |
GO:00509213 | Cervix | CC | positive regulation of chemotaxis | 34/2311 | 141/18723 | 8.19e-05 | 1.11e-03 | 34 |
GO:00518964 | Cervix | CC | regulation of protein kinase B signaling | 39/2311 | 185/18723 | 5.25e-04 | 5.10e-03 | 39 |
GO:19018886 | Cervix | CC | regulation of cell junction assembly | 42/2311 | 204/18723 | 5.50e-04 | 5.29e-03 | 42 |
GO:00518973 | Cervix | CC | positive regulation of protein kinase B signaling | 28/2311 | 120/18723 | 5.90e-04 | 5.59e-03 | 28 |
GO:00434913 | Cervix | CC | protein kinase B signaling | 43/2311 | 211/18723 | 5.95e-04 | 5.60e-03 | 43 |
GO:00519603 | Cervix | CC | regulation of nervous system development | 77/2311 | 443/18723 | 1.13e-03 | 9.30e-03 | 77 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TPBG | SNV | Missense_Mutation | c.1198N>T | p.His400Tyr | p.H400Y | Q13641 | protein_coding | deleterious(0) | probably_damaging(0.946) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
TPBG | SNV | Missense_Mutation | novel | c.805N>A | p.Ala269Thr | p.A269T | Q13641 | protein_coding | deleterious(0.04) | possibly_damaging(0.556) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TPBG | SNV | Missense_Mutation | c.602N>T | p.Ala201Val | p.A201V | Q13641 | protein_coding | deleterious(0.02) | benign(0.01) | TCGA-AA-3815-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TPBG | SNV | Missense_Mutation | c.1133N>A | p.Arg378His | p.R378H | Q13641 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
TPBG | SNV | Missense_Mutation | novel | c.863N>T | p.Arg288Met | p.R288M | Q13641 | protein_coding | deleterious(0) | benign(0.436) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
TPBG | SNV | Missense_Mutation | c.1220N>T | p.Ala407Val | p.A407V | Q13641 | protein_coding | deleterious(0) | possibly_damaging(0.715) | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TPBG | SNV | Missense_Mutation | novel | c.983N>T | p.Lys328Ile | p.K328I | Q13641 | protein_coding | deleterious(0.05) | benign(0.326) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
TPBG | insertion | Frame_Shift_Ins | novel | c.185_186insC | p.Ala64ArgfsTer16 | p.A64Rfs*16 | Q13641 | protein_coding | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | ||
TPBG | SNV | Missense_Mutation | novel | c.545N>G | p.His182Arg | p.H182R | Q13641 | protein_coding | tolerated(0.44) | benign(0) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
TPBG | SNV | Missense_Mutation | novel | c.491G>A | p.Gly164Asp | p.G164D | Q13641 | protein_coding | tolerated(0.64) | benign(0.241) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7162 | TPBG | CELL SURFACE, DRUGGABLE GENOME | CHEMBL1743045 | NAPTUMOMAB ESTAFENATOX | ||
7162 | TPBG | CELL SURFACE, DRUGGABLE GENOME | antibody | 374883834 | ||
7162 | TPBG | CELL SURFACE, DRUGGABLE GENOME | CHEMBL2108248 | ANATUMOMAB MAFENATOX | ||
7162 | TPBG | CELL SURFACE, DRUGGABLE GENOME | PF-06263507 | PF-06263507 | ||
7162 | TPBG | CELL SURFACE, DRUGGABLE GENOME | Naptumomab estafenatox | |||
7162 | TPBG | CELL SURFACE, DRUGGABLE GENOME | CV-9201 | |||
7162 | TPBG | CELL SURFACE, DRUGGABLE GENOME | TroVax | TROVAX | ||
7162 | TPBG | CELL SURFACE, DRUGGABLE GENOME | antibody | 374883835 |
Page: 1 |